Mirion to Detail Financial Targets and Long-term Strategy at Today's Investor Day

$MIR
Industrial Machinery/Components
Industrials
Get the next $MIR alert in real time by email

Leadership team to outline unique position within growing nuclear and cancer care markets

Mirion ("we" or the "company") (NYSE:MIR), a leading provider of radiation safety solutions supporting advancements in nuclear power and cancer care, will host an Investor Day today, December 3, 2024, at 2:00pm ET. The event will be held at the New York Stock Exchange in New York, NY. In-person attendance requires prior registration. Interested parties may access the livestream of the event, related published materials and a replay of the event by accessing Mirion's IR website at ir.mirion.com.

The event will feature presentations by members of Mirion's leadership team, followed by a live question-and-answer session.

The Mirion management team will discuss the company's updated strategic and financial outlook, including:

  • Promising market tailwinds supporting nuclear power growth opportunities amidst new builds, the installed base and small modular reactor development;
  • An update on cancer care market dynamics in both radiation therapy and nuclear medicine;
  • A discussion of the company's commitment to commercial and operational excellence;
  • Advancements in digital and innovation strategies taking shape across the enterprise;
  • Initial 2025 guidance and a long-term financial outlook for 2028;
  • The announcement of an anti-dilutive and opportunistic share repurchase program; and
  • An update to the company's capital allocation strategy.

"This is a very exciting time in Mirion's history, and I am thrilled to share our updated strategy and outlook with the investment community," stated Mirion's CEO, Thomas Logan. "We are uniquely positioned in the middle of two super trends taking place in nuclear power and cancer care, which I expect to deliver robust growth for the business in the years to come. With our focus on commercial and operational excellence, I am confident in our approach to expand and protect shareholder value in the short- and longer-term."

Financial Projections

2028 Long-Term Financial Outlook

At the Investor Day, Mirion will provide its 2028 long-term financial outlook, including projected:

  • Revenue of approximately $1.1 billion by 2028, assuming approximately 6% - 8% organic revenue growth
  • Adjusted EBITDA margin of approximately 30% by 2028
  • Adjusted Free Cash Flow Conversion of approximately 60% of adjusted EBITDA by 2028; interim target of approximately 50% of adjusted EBITDA by 2026

Organic revenue growth guidance excludes the impact of foreign exchange rates as well as any mergers, acquisitions and divestitures. Other modeling and guidance assumptions will be included in the appendix of the Investor Day presentation.

Initial 2025 Financial Guidance

In addition, Mirion will provide initial 2025 financial guidance, including:

  • Organic revenue growth of approximately 5.5% - 7.5%; includes an approximately 30 basis point lasers business divestiture headwind from 2024
  • Revenue growth of approximately 4.0% - 6.0%; includes a foreign exchange rate headwind of approximately 150 basis points
  • Adjusted EBITDA and adjusted EBITDA margin of approximately $215 million - $230 million and 24.5% - 25.5%, respectively; includes a foreign exchange rate headwind to adjusted EBITDA of approximately $3.5 million
  • Adjusted Free Cash Flow of approximately $85 million - $110 million; adjusted Free Cash Flow Conversion of approximately 39% - 48% of Adjusted EBITDA
  • Assumes a 1.05 Euro-to-USD foreign exchange rate

The company's guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading "Forward-Looking Statements." In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion's control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for organic and inorganic revenue, adjusted EBITDA, adjusted EPS and adjusted free cash flow are not available without unreasonable effort.

Strategic Partnership

Memorandum of Understanding Signed with Electronics Corporation of India Ltd

Mirion signed, with its Indian partner AdvanceTech, a Memorandum of Understanding with Electronics Corporation of India Ltd (ECIL), the leading player in this market, to support the rapid growth of India's nuclear sector. This partnership will leverage Mirion's expertise in advanced radiation monitoring systems and ECIL's local manufacturing and market insights to jointly fabricate, assemble, test, and supply radiation monitors. Through this collaboration, both companies aim to address the demands of India's nuclear infrastructure expansion.

Share Repurchase Program

Will announce a $100 million share repurchase program

The company will also announce a share repurchase program for up to $100 million of the currently outstanding shares of the company's Class A common stock, as approved by the Board of Directors of the company. The share repurchase program is designed to mitigate the going forward dilutive impact of shares issued under the company's 2021 Omnibus Incentive Plan and to provide management with capital structure flexibility while concurrently managing objectives related to balance sheet leverage, acquisition opportunities, and shareholder returns. Under the share repurchase program, the company intends to repurchase shares through open market purchases, privately negotiated transactions, block purchases or otherwise in accordance with applicable federal securities laws, including Rule 10b-18 of the Securities Exchange Act of 1934 (the "Exchange Act").

The Board also authorized the company to enter into written trading plans under Rule 10b5-1 of the Exchange Act. Adopting a trading plan that satisfies the conditions of Rule 10b5-1 allows a company to repurchase its shares at times when it might otherwise be prevented from doing so due to self-imposed trading blackout periods or pursuant to insider trading laws. Under any Rule 10b5-1 trading plan, the company's third-party broker, subject to United States Securities and Exchange Commission regulations regarding certain price, market, volume and timing constraints, would have authority to purchase the company's Class A common stock in accordance with the terms of the plan. The company may from time to time enter into Rule 10b5-1 trading plans to facilitate the repurchase of its Class A common stock pursuant to its share repurchase program.

The company cannot predict when or if, or at what prices, it will repurchase any shares of Class A common stock as such stock repurchase program will depend on a number of factors, including constraints specified in any Rule 10b5-1 trading plans, price, general business and market conditions, the terms of the company's debt agreements and alternative investment opportunities. Further, the stock repurchase program may be suspended or terminated at any time by the company without prior notice. Information regarding share repurchases will be available in the company's periodic reports on Form 10-Q and 10-K filed with the Securities and Exchange Commission as required by the applicable rules of the Exchange Act.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 21E of the Exchange Act , as amended. Words such as "anticipate", "believe", "continue", "could", "estimate", "expect", "hope", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "should", "strive", "seeks", "plans", "would", "will", "understand" and similar words are intended to identify forward looking statements, but the absence of these words does not mean that a statement is not forward looking. These forward-looking statements include but are not limited to, statements regarding our future operating results, financial position and guidance, our business strategy and plans, our objectives for future operations, our strategic partnership with EDF, the closure of our lasers business, macroeconomic trends, trends in cancer care, nuclear power and small modular reactor, foreign exchange, interest rate and inflation expectations, any future mergers, acquisitions, divestitures and strategic investments, including the completion and integration of previously completed transactions, and our future share capitalization. These forward-looking statements, including any financial guidance, do not reflect, and make no positive or negative assumptions regarding, any policies, laws or regulations that may be introduced, promulgated or implemented by the newly elected United States president or Congress. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including changes in domestic and foreign business, market, economic, financial, political and legal conditions, including related to matters affecting Russia, the relationship between the United States and China, conflict in the Middle East and risks of slowing economic growth or economic recession in the United States and globally; developments in the government budgets (defense and non-defense) in the United States and other countries, including budget reductions, sequestration, implementation of spending limits or changes in budgetary priorities, delays in the government budget process, a U.S. government shutdown or the U.S. government's failure to raise the debt ceiling; risks related to the public's perception of nuclear radiation and nuclear technologies; risks related to the continued growth of our end markets; our ability to win new customers and retain existing customers; our ability to realize sales expected from our backlog of orders and contracts; risks related to governmental contracts; our ability to mitigate risks associated with long-term fixed price contracts, including risks related to inflation; risks related to information technology system failures or other disruptions or cybersecurity, data security or other security threats; risks related to the implementation and enhancement of information systems; our ability to manage our supply chain or difficulties with third-party manufacturers; risks related to competition; our ability to manage disruptions of, or changes in, our independent sales representatives, distributors and original equipment manufacturers; our ability to realize the expected benefit from strategic transactions, such as acquisitions, divestitures, investments and partnerships, including any synergies, or internal restructuring and improvement efforts; our ability to issue debt, equity or equity-linked securities in the future; risks related to changes in tax law and ongoing tax audits; risks related to future legislation and regulation both in the United States and abroad; risks related to the costs or liabilities associated with product liability claims; risks related to the uncertainty of legal claims, litigation, arbitration and similar proceedings; our ability to attract, train and retain key members of our leadership team and other qualified personnel; risks related to the adequacy of our insurance coverage; risks related to the global scope of our operations, including operations in international and emerging markets; risks related to our exposure to fluctuations in foreign currency exchange rates, interest rates and inflation, including the impact on our debt service costs; our ability to comply with various laws and regulations and the costs associated with legal compliance; risks related to the outcome of any litigation, government and regulatory proceedings, investigations and inquiries; risks related to our ability to protect or enforce our proprietary rights on which our business depends or third-party intellectual property infringement claims; liabilities associated with environmental, health and safety matters; our ability to predict our future operational results; the effects of health epidemics, pandemics and similar outbreaks may have on our business, results of operations or financial condition; and the amount, timing, price or form of share repurchases, if any, that we may make. Further information on risks, uncertainties and other factors that could affect our financial results are included in the filings we make with the United States Securities and Exchange Commission (the "SEC") from time to time, including our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and other periodic reports filed or to be filed with the SEC.

You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Use of Non-GAAP Financial Information

In addition to our results determined in accordance with GAAP, we believe that the presentation of non-GAAP financial information provides important supplemental information to management and investors regarding financial and business trends relating to our financial condition and results of operations. For further information regarding our previously reported non-GAAP measures, including the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, please refer to full reconciliations, non-GAAP definitions and forward-looking statements available in the 3Q 2024 earnings presentation (link) and the 2024 Investor Day presentation to be posted on ir.mirion.com.

Channels for Disclosure of Information

Mirion intends to announce material information to the public through the Mirion Investor Relations website ir.mirion.com, SEC filings, press releases, public conference calls and public webcasts. Mirion uses these channels, as well as social media, to communicate with its investors, customers, and the public about the company, its offerings, and other issues. It is possible that the information Mirion posts on social media could be deemed to be material information. As such, Mirion encourages investors, the media, and others to follow the channels listed above, including the social media channels listed on Mirion's investor relations website, and to review the information disclosed through such channels. Any updates to the list of disclosure channels through which Mirion will announce information will be posted on the investor relations page on Mirion's website.

About Mirion

Mirion (NYSE:MIR) is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. The Mirion Technologies group provides proven radiation safety technologies that operate with precision – for essential work within R&D labs, critical nuclear facilities, and on the front lines. The Mirion Medical group solutions help enhance the delivery and ensure safety in healthcare, powering the fields of Nuclear Medicine, Radiation Therapy QA, Occupational Dosimetry, and Diagnostic Imaging. Headquartered in Atlanta (GA – USA), Mirion employs approximately 2,800 people and operates in 12 countries. Learn more at mirion.com.

Get the next $MIR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Q&A

New
  • What is the purpose of the Investor Day hosted by Mirion?

    Mirion is hosting an Investor Day to present their strategic and financial outlook, focusing on opportunities in the nuclear power and cancer care markets.

  • Who from Mirion will present at the Investor Day?

    Thomas Logan, the CEO of Mirion, will deliver presentations during the event discussing the company's strategy and market positioning.

  • What financial projections will Mirion provide at the Investor Day?

    Mirion has projected approximately $1.1 billion in revenue by 2028, assuming about 6% - 8% organic revenue growth, along with an adjusted EBITDA margin of approximately 30%.

  • What strategic partnership is Mirion announcing during the event?

    Mirion has signed a Memorandum of Understanding with Electronics Corporation of India Ltd to support the growth of India's nuclear sector, leveraging local manufacturing and expertise.

  • What are the upcoming financial strategies mentioned by Mirion?

    The company plans to initiate a share repurchase program of up to $100 million to mitigate dilution from its previous incentive plans and provide financial flexibility.

Recent Analyst Ratings for
$MIR

DatePrice TargetRatingAnalyst
12/19/2024$22.00Outperform
Robert W. Baird
9/26/2024$14.00Buy
B. Riley Securities
5/26/2023$11.00Buy
Citigroup
3/24/2022$13.00Market Outperform
CJS Securities
11/29/2021$14.00Buy
Goldman Sachs
10/25/2021$14.00Buy
Citigroup
More analyst ratings

$MIR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Mirion Technologies Joins Influential Nuclear Energy Organizations to Further Bolster Nuclear Initiatives

    Mirion joins the Nuclear Energy Institute, enhances membership with the American Nuclear Society as a Trustees of Nuclear partner. Mirion (NYSE:MIR), a leading provider of advanced radiation safety solutions, today announced that it has joined the Nuclear Energy Institute (NEI) and the American Nuclear Society's (ANS) Trustees of Nuclear program. Membership in the two preeminent nuclear industry and professional organizations in the United States provides Mirion Technologies with an enhanced platform to engage with industry leaders and policymakers, as well as share industry expertise, on issues of importance to the nuclear sector. NEI is the policy organization of the nuclear energy indu

    $MIR
    Industrial Machinery/Components
    Industrials
  • Mirion to Present at the 46th Annual Raymond James Institutional Investor Conference

    Mirion (NYSE:MIR) announced today that Chief Executive Officer, Thomas Logan, and Chief Financial Officer, Brian Schopfer, will present at the 46th Annual Raymond James Institutional Investor Conference. The presentation will begin at 9:15 a.m. ET on Wednesday, March 5, 2025. The presentation will be webcast live at Mirion's Investor Relations Page. The link will be displayed under the "Events and Presentations" section. An archive of the webcast will be available as well at the same location. About Mirion Mirion (NYSE:MIR) is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of

    $MIR
    Industrial Machinery/Components
    Industrials
  • Mirion to Present at Citi's 2025 Global Industrial Tech and Mobility Conference

    Mirion (NYSE:MIR) announced today that Chief Executive Officer, Thomas Logan, and Chief Financial Officer, Brian Schopfer, will present at Citi's 2025 Global Industrial Tech and Mobility Conference in Miami, FL. The presentation will begin at 2:40 PM ET on Wednesday, February 19, 2025. The presentation will be webcast live at Mirion's Investor Relations Page where a webcast link will be displayed under the "Events and Presentations" section. An archive of the webcast will be available as well at the same location. About Mirion Mirion (NYSE:MIR) is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transf

    $MIR
    Industrial Machinery/Components
    Industrials

$MIR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MIR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MIR
SEC Filings

See more

$MIR
Leadership Updates

Live Leadership Updates

See more
  • Sun Nuclear® Solutions Supporting Better Patient Care in Focus at ASTRO 2023

    SunCHECK® Platform Enhancements, New MRgRT QA Solutions, and More MELBOURNE, Fla., Sept. 29, 2023 /PRNewswire/ -- Sun Nuclear, a Mirion Medical company (NYSE:MIR), will showcase enhancements and additions to its comprehensive Quality Management portfolio at the ASTRO Annual Meeting, October 1-3, in San Diego, California. The Sun Nuclear booth (#1835) will highlight new features and insights for the SunCHECK® Platform, new MR capabilities for proven SRS/SBRT QA solutions, and the new SIM+™ Pro laser system for patient alignment. Complete Quality Management in One PlatformAvail

    $MIR
    Industrial Machinery/Components
    Industrials
  • Janus International Appoints David Vanevenhoven as Chief Accounting Officer

    Brings over 15 years of accounting and M&A auditing experience to further enhance Janus's financial reporting and integration capabilities Janus International Group, Inc. (NYSE:JBI) ("Janus" or the "Company"), a leading provider of cutting-edge access control technologies and building product solutions for the self-storage and other commercial and industrial sectors, today announced the appointment of David Vanevenhoven as Chief Accounting Officer, on February 20, 2023. He will report directly to Janus's CFO, Anselm Wong. Mr. Vanevenhoven brings over 15 years of experience in financial accounting and auditing to oversee Janus's accounting function, financial reporting, and internal control

    $JBI
    $MIR
    Building Products
    Industrials
    Industrial Machinery/Components
  • Mirion Technologies Appoints Michael Rossi as President of Mirion Medical

    Mirion Technologies, Inc. ("Mirion," "we" or the "Company") (NYSE:MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced the appointment of Michael Rossi as the President of Mirion Medical. Michael will report directly to Mirion's CEO, Tom Logan, who had been acting as President of the business segment. Michael joins Mirion from Novartis, where he most recently served as the Head of Radioligand Imaging for the Advanced Accelerator Applications business. Prior to Novartis, Michael spent five years at Jubilant Pharma where he served in several different roles with increasing le

    $MIR
    Industrial Machinery/Components
    Industrials

$MIR
Financials

Live finance-specific insights

See more
  • Mirion Announces Record Fourth Quarter and Record Full Year 2024 Financial Results; Reaffirms Full Year 2025 Guidance

     Revenues for the fourth quarter increased 10.4% to $254.3 million, compared to $230.4 million in the same period in 2023. GAAP net income was $15.9 million in the fourth quarter, compared to a GAAP net loss of $14.5 million in the same period last year; a 210% improvement. Adjusted EBITDA was $69.6 million, a 14.1% increase from $61.0 million in the same period last year. GAAP net earnings per share in the fourth quarter was $0.07, compared to a GAAP net loss per share of $0.08 in the fourth quarter of 2023. Adjusted earnings per share for the quarter was $0.17, compared to $0.15 in the same period last year. The company reaffirmed its full year 2025 guidance provided at the Dece

    $MIR
    Industrial Machinery/Components
    Industrials
  • Mirion Announces Earnings Release and Conference Call Date for Fourth Quarter and Full Year 2024

    Mirion (NYSE:MIR) announced today that it will release financial results for fourth quarter and full year 2024 after market close on Tuesday, February 11, 2025. Following the news release, the company will host a conference call the next day, Wednesday, February 12, 2025, at 11:00 am ET to discuss the results. Participants may access the call by dialing 1-877-407-9208 or 1-201-493-6784, and requesting to join the Mirion Technologies, Inc. earnings call. A live webcast will also be available at https://ir.mirion.com/news-events. A telephonic replay will be available shortly after the conclusion of the call and until February 26, 2025. Participants may access the replay at 1-844-512-2921

    $MIR
    Industrial Machinery/Components
    Industrials
  • Mirion Announces Third Quarter 2024 Financial Results and Updates Full Year Guidance

    Revenues for the third quarter increased 8.2% to $206.8 million, compared to $191.2 million in the same period in 2023. Net loss was $14.0 million in the third quarter, compared to a net loss of $12.9 million in the same period last year. Adjusted EBITDA was $45.7 million, a 17.8% increase from $38.8 million in the same period last year. Loss from operations margin was 0.8% in the third quarter, compared to 5.8% in the same period in 2023. Adjusted EBITDA margin was 22.1% in the third quarter, compared to 20.3% in the same period last year. GAAP net loss per share for the third quarter was $0.07, compared to $0.06 in the third quarter of 2023. Adjusted earnings per share for the q

    $MIR
    Industrial Machinery/Components
    Industrials

$MIR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more